Qilu Pharmaceutical's Antineoplastic Drug Pomalidomide Capsules (Youboan®) Approved for Market Launch in China

On June 3, according to the official website of the National Medical Products Administration,Qilu Pharmaceutical's Anti-Tumor Drug Pomalidomide Capsules (Youboan®) Officially Receive Marketing Approval.The approval and market launch of Qilu Pharmaceutical's Youboan® will provide a new treatment strategy for the long-term clinical control of multiple myeloma.

Source of the image:National Medical Products Administration

Multiple myeloma is a malignant disease characterized by the clonal proliferation of abnormal plasma cells and is one of the common malignant tumors of the hematological system. Currently,The incidence of multiple myeloma in China has surpassed that of acute leukemia, making it the second most common malignant tumor in the hematological system.

As a third-generation immunomodulatory agent, pomalidomide demonstrates unique effects such as anti-infection, immunomodulation, anti-tumor proliferation, and anti-tumor angiogenesis. It has shown promising efficacy and lower toxicity in clinical trials targeting refractory and relapsed multiple myeloma.

Currently, the original pomalidomide was developed by Celgene and received approval from the U.S. Food and Drug Administration (FDA) for marketing in February 2013.Original Research PomalidomideNot yet available in China. The newly approved pomalidomide capsules cover four clinical specifications, compared to the pomalidomide capsules currently available in China,Two new specifications, 2mg and 3mg, are more suitable for patients with mild to severe hepatic and renal impairment., more convenient for dose adjustment.